Stable Angina – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Stable angina, or typical angina or angina pectoris, is a symptom of myocardial ischemia, characterized by chest discomfort or anginal equivalent triggered by exertion and relieved at rest or with nitroglycerin. This symptom arises from a supply-demand mismatch, where myocardial oxygen demand momentarily surpasses supply, often manifesting symptoms. The primary cause of stable angina is coronary artery stenosis, most frequently experienced during or after exercise, particularly in individuals with atherosclerosis. This condition leads to inadequate blood and oxygen delivery to actively respiring myocardial tissue, causing ischemia without myocardial necrosis, reflected in mostly normal biomarkers in blood. However, cardiac troponin release can aid in risk assessment. Chronic stable angina, recurring at a fixed rate-pressure product, contrasts with unstable and variant angina. Variant angina, or Prinzmetal angina, stems from coronary artery vasospasm, potentially leading to infarction but typically managed with vasodilators. Unstable angina, occurring at rest or waking patients at night, signifies a critical warning of impending myocardial infarction, also known as preinfarction angina. Chronic stable angina worsening with reduced exercise intensity may also indicate instability. In managing chronic stable angina, antianginal therapy continuity is vital perioperatively, with β-blockers maintained until the operation, preferably using long-acting preparations like nadolol or atenolol. Intravenous administration, such as propranolol, metoprolol, or esmolol, may be necessary if oral intake is delayed postoperatively, with a prompt shift back to oral therapy. Patients on long-term calcium channel antagonist treatment often receive oral preparations preoperatively, switching to intravenous or topical nitrates if oral intake is delayed, with intravenous options limited to verapamil and diltiazem.
Thelansis’s “Stable Angina Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stable Angina treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Stable Angina across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Stable Angina Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment